Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half
Year Results
14.08.2012 / 07:40
---------------------------------------------------------------------
Berlin, August 14, 2012. The Eckert & Ziegler Group (ISIN DE0005659700), a
specialist in isotope applications in medicine, science and industry
increased its group revenues by EUR 2.1 million (+4%) in the first half
year 2012 to EUR 57.9 million. EBIT resulted in EUR 10.0 million (-16%);
earnings after taxes and minority interests amounted to EUR 5.4 million
(-17%) or EUR 1.03 per share (-18%). The relative decline in earnings was
solely the result of a very strong start of the year 2011; based on the
entire year, revenue is according to plan.
The largest share of overall earnings is made up by the Isotope Products
segment. In this segment, revenues with external customers increased
slightly by 2% to EUR 28.2 million. This resulted in an EBIT of EUR 9.1
million, thereby exceeding the previous year by 4%.
Also encouraging is the revenue growth of 7% to EUR 14.0 million in the
Radiation Therapy segment. In this segment, the new MultiSource(R) cancer
radiation system was responsible for a boost in revenues. Compared to the
same period of the previous year, expenditures for research and development
have more than doubled in the segment. As a result, EBIT decreased by 35%
to EUR 0.9 million. Comprehensive statements about the Radiation Therapy
segment can be found in the quarterly report of Eckert & Ziegler BEBIG s.a.
(www.bebig.eu) which is released at the same time.
In the Radiopharma segment, growth experienced a slowdown. Thanks to the
acquisition of Bioscan in the previous year, the segment achieved a revenue
growth of 2% to EUR 12.7 million. Compared to the same period last year,
expenditures in the production and sales areas increased. As a result, EBIT
decreased by 37% to EUR 1.4 million. However, if the second quarter of 2012
is viewed in isolation, it reveals a positive trend: Compared to the same
period of the previous year, EBIT increased during the last three months by
22% to EUR 0.9 million.
The strongest growth was in the Environmental Services segment. Revenues
with external customers increased by 19% to EUR 3.1 million. However, the
first six months of 2012 contain cost restructuring. For this reason, EBIT
shows a loss of EUR 0.6 million. In the next few quarters, the segment is
not yet expected to make a positive contribution to earnings.
To read the full report please click here:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz212e.pdf
Sales of approx. EUR 117 million and a result after tax and minority
interests of approx. EUR 10 million are expected for the fiscal year 2012.
With around 600 employees the Eckert & Ziegler Group belongs to the largest
providers of isotope components for radiotherapy and nuclear medicine
worldwide.
If you have any questions please contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138
karolin.riehle@ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
14.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
181486 14.08.2012
